|
業務類別
|
Biotechnology |
|
業務概覽
|
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer'sdisease psychosis, Lewy Body Dementia psychosis, and multiple other programs. |
| 公司地址
| 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 558-2871 |
| 傳真號碼
| +1 858 212-0513 |
| 公司網頁
| https://www.acadia.com |
| 員工數量
| 798 |
| Ms. Jennifer J. Rhodes |
Executive Vice President, Chief Legal Officer and Secretary |
美元 538.78K |
24/04/2026 |
| Mr. James K. Kihara |
Senior Vice President, Finance, Controller and Chief Accounting Officer |
-- |
26/02/2026 |
| Mr. Mark C. Schneyer |
Executive Vice President and Chief Financial Officer |
美元 546.43K |
24/04/2026 |
| Mr. Thomas A. Garner |
Executive Vice President and Chief Commercial Officer |
美元 525.00K |
24/04/2026 |
| Ms. Catherine Owen Adams |
Director and Chief Executive Officer |
美元 930.00K |
24/04/2026 |
|
|
| Mr. Julian C. Baker |
Independent Director |
24/04/2026 |
| Ms. Laura A. Brege |
Independent Director |
24/04/2026 |
| Dr. Stephen R. Biggar,M.D.,PhD |
Chairman of the Board |
24/04/2026 |
| Dr. Edmund P. Harrigan, M.D. |
Independent Director |
24/04/2026 |
| Mr. James M. Daly |
Independent Director |
24/04/2026 |
| Mr. Jonathan Poole |
Director |
05/03/2026 |
| Dr. Elizabeth A. Garofalo, M.D. |
Independent Director |
24/04/2026 |
| Dr. Adora Ndu, Pharm.D. |
Independent Director |
24/04/2026 |
| Ms. Catherine Owen Adams |
Director and Chief Executive Officer |
24/04/2026 |
|
|
|
|